Review: mitochondrial quality control in human ageing and longevity
This review summarizes current understanding of mitochondrial quality control in healthy human longevity, how its dysregulation in ageing affects metabolism and immune function, and emerging strategies such as NAD, AMPK activators and caloric restriction. [1]
Automatic summary · not editorially reviewed
The key findings
Mitochondrial quality control monitors organelle integrity and function and repairs or removes damaged mitochondria, replacing them with newly formed healthy ones. [1]
The review explains how dysregulation of mitochondrial quality control in ageing negatively impacts systemic metabolism and immune function. [1]
Emerging therapeutic strategies discussed include NAD, AMPK activators and caloric restriction, and quality control is presented as a potential gerotherapeutic target for preclinical and clinical studies. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Humans in the context of healthy ageing and longevity, as discussed in a review
- Summary based on
- Study abstract
- Original publication
- June 29, 2026
Mitochondrial quality control and healthy longevity
Mitochondria are central to cellular metabolism and to inflammation, stress response, cell death and signalling. Quality control mechanisms monitor organelle integrity and function and repair or remove damaged mitochondria, replacing them with newly formed healthy ones. The review focuses on this biology in the context of healthy human longevity.
Supporting source [1]
Dysregulation in ageing and proposed strategies
The authors describe how quality control is regulated under physiological conditions and explain how its dysregulation in ageing negatively affects systemic metabolism and immune function. They discuss emerging therapeutic strategies, such as NAD, AMPK activators and caloric restriction, that aim to maintain robust quality control and improve metabolic resilience.
Supporting source [1]
Preclinical and clinical routes to a gerotherapeutic target
The review illustrates how preclinical and clinical studies can use mitochondrial quality control as a potential gerotherapeutic target. It notes that failure of quality control paves the way to chronic diseases such as diabetes, metabolic syndromes and immunosenescence. These are described as potential directions, not established treatments.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no study design, sample, follow-up or outcome data, and the therapeutic strategies are described as emerging and potential, not established benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Picca A, Ferrucci L. · europepmc.org · June 29, 2026